Luca Castagna

Luca Castagna

Palermo, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 214 publications

In vivo T-cell depletion and pharmacokinetic-based busulfan conditioning regimen improve the outcomes in acute myeloid leukemia (AML) in complete remission undergoing to allogeneic stem cell transplantation.

In vivo T-cell depletion and pharmacokinetic-based busulfan conditioning regimen improve the outcomes in acute myeloid leukemia (AML) in complete remission undergoing to allogeneic stem cell transplantation.

Journal: Cancer

Published: August 15, 2026

Real-world approaches to preventing acute myeloid leukemia relapse after allogeneic transplantation: a national survey by GITMO (Gruppo Italiano Trapianto Midollo Osseo).

Real-world approaches to preventing acute myeloid leukemia relapse after allogeneic transplantation: a national survey by GITMO (Gruppo Italiano Trapianto Midollo Osseo).

Journal: Bone marrow transplantation

Published: April 01, 2026

A Bayesian Survival Model to Support the Selection of the Best Hematopoietic Stem Cell Donor.

A Bayesian Survival Model to Support the Selection of the Best Hematopoietic Stem Cell Donor.

Journal: Transplantation and cellular therapy

Published: March 17, 2026

Diagnostic delay of veno-occlusive disease in a myelofibrosis patient with pre-transplant transjugular intrahepatic portosystemic shunt: a case report.

Diagnostic delay of veno-occlusive disease in a myelofibrosis patient with pre-transplant transjugular intrahepatic portosystemic shunt: a case report.

Journal: Frontiers in oncology

Published: March 01, 2026

Autologous and allogeneic haematopoietic cell transplantation in adult patients with Hodgkin lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee and Lymphoma Working Party.

Autologous and allogeneic haematopoietic cell transplantation in adult patients with Hodgkin lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee and Lymphoma Working Party.

Journal: The Lancet. Haematology

Published: February 03, 2026

The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL).

The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL).

Journal: Bone marrow transplantation

Published: February 02, 2026

Treatment of Acute Myeloid Leukemias and Myelodisplastic Syndromes Relapsing After Allogeneic Stem Cell Transplantation: An In-Depth Analysis of the GITMO AML/MDS-Relapse Registry Study.

Treatment of Acute Myeloid Leukemias and Myelodisplastic Syndromes Relapsing After Allogeneic Stem Cell Transplantation: An In-Depth Analysis of the GITMO AML/MDS-Relapse Registry Study.

Journal: Clinical lymphoma, myeloma & leukemia

Published: January 22, 2026

Lymphodepletion and donor lymphocyte infusions (LD-DLI) for DLI-non responsive myelofibrosis.

Lymphodepletion and donor lymphocyte infusions (LD-DLI) for DLI-non responsive myelofibrosis.

Journal: Bone marrow transplantation

Published: January 14, 2026

Real-world outcomes in refractory chronic graft-versus-host disease: the Italian multicenter experience with belumosudil.

Real-world outcomes in refractory chronic graft-versus-host disease: the Italian multicenter experience with belumosudil.

Journal: Haematologica

Published: September 29, 2025

Incidence and outcome of hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: a survey of the infectious diseases working party of EBMT.

Incidence and outcome of hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: a survey of the infectious diseases working party of EBMT.

Journal: Bone marrow transplantation

Published: September 19, 2025

Trends in GVHD Epidemiology, Prophylaxis and Management: The Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO) GVHD24 Study.

Trends in GVHD Epidemiology, Prophylaxis and Management: The Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO) GVHD24 Study.

Journal: American journal of hematology

Published: August 22, 2025

Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study.

Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study.

Journal: British journal of haematology

Published: July 29, 2025

Showing 1-12 of 214

Last Updated: 09/26/2026